SOURCE: Oracle Corporation

Oracle Corporation

March 25, 2014 08:14 ET

Oracle Health Sciences InForm Advanced Molecular Analytics Enables Life Sciences Organizations to Incorporate Genomic Data Into Clinical R&D for Targeted, Biomarker-Driven Clinical Trials

Solution Extends the Capabilities of Oracle Health Sciences InForm GTM to Effectively Collect, Store and Analyze Genomic Data

BOSTON, MA--(Marketwired - Mar 25, 2014) - ORACLE INDUSTRY CONNECT -- Oracle (NYSE: ORCL)

News Summary
Biomarkers are becoming a key component of clinical trial design, enabling researchers to rapidly find subjects with similar clinical and omics characteristics. Oracle Health Sciences InForm Advanced Molecular Analytics is one of the first commercially available cloud-delivery solutions to incorporate genomics into the clinical data capture and management process. Integrated with Oracle Health Sciences InForm GTM, the solution enables clinical researchers to effectively capture, aggregate and analyze molecular data along with clinical data to provide the information needed to identify new predictive biomarkers. The solution facilitates the stratification of patients into target populations of responders to accelerate trials and improve drug and therapeutic outcomes.

News Facts

  • Oracle Health Sciences today announced Oracle Health Sciences InForm Advanced Molecular Analytics. Integrated with Oracle Health Sciences InForm GTM, the solution enables clinical trial managers to systematically and effectively collect, store and analyze genomic data captured in a clinical trial.
  • The new capabilities of Oracle Health Sciences InForm Advanced Molecular Analytics help life sciences organizations to stratify patients and reduce research and development costs by leveraging targeted drug development approaches and decreasing study size and length. The solution also helps researchers identify new indications and therapies through post-trial, cross-study analysis with molecular data.
  • Collecting biomarker data is typically a difficult manual effort, aggregating data scattered across spreadsheets, file systems and siloed transaction systems. With Oracle Health Sciences InForm Advanced Molecular Analytics, researchers have consolidated access to both clinical and genomic data for numerous purposes, such as submission or the design of more exploratory translational research studies, including those that can generate petabytes of data from thousands of whole genome sequences.
  • Life sciences organizations can gain a single, integrated view of genomic, genetic and clinical data, enabling clinical researchers to identify and validate new targets. The solution supports multiple omics modalities and targeted gene panels and can scale to handle hundreds of thousands of whole genomes.
  • Clinical researchers can study patient genomic profiles, analyze differences and compare molecular data against common large public domain data sets, such as The Cancer Genome Atlas -- streamlining analysis and increasing statistical power.
  • The Oracle Health Sciences InForm Advanced Molecular Analytics solution leverages proven technology from Oracle Health Sciences Translational Research Center to deliver one of the first commercially available "molecular-aware" clinical data capture and management solutions.
  • Oracle Health Sciences InForm Advanced Molecular Analytics is deployed as software-as-a-service (SaaS) and is fully integrated with the Oracle Health Sciences InForm Cloud Service. As a comprehensive and commercially available SaaS solution, life sciences organizations avoid the cost and time associated with building and maintaining custom solutions.

Supporting Quotes

  • "As clinical trial design advances and becomes more targeted, new dynamics emerge in clinical research and development, such as the increasing need to quickly and reliably identify and validate biomarker hypotheses," said Mukhtar Ahmed, global vice president of product strategy, Oracle Health Sciences. "Oracle Health Sciences InForm Advanced Molecular Analytics expands the industry leading capabilities of Oracle Health Sciences InForm with new genomic management and analysis capabilities to facilitate more targeted trial design and drug development."
  • "The adoption of our translational research platform in the healthcare sector by top-tier academic medical centers demonstrates that our genomics solutions have been tried, tested and shown to scale at an enterprise level," said Jonathan Sheldon, PhD, global vice president, Oracle Health Sciences. "With the release of Oracle Health Sciences InForm Advance Molecular Analytics, we are delivering a 'biomarker-aware' clinical platform to help enable sponsors to design more targeted genomics studies."

Supporting Resources

About Oracle
Oracle engineers hardware and software to work together in the cloud and in your data center. For more information about Oracle (NYSE: ORCL), visit

About Oracle Health Sciences
At Oracle, we believe that a more predictive, preventive, personalized and participatory system will help improve human health. We can help accelerate this journey to personalized medicine through technology, data and insights. Oracle's solutions support industry initiatives to improve care quality and outcomes, reduce costs, and speed time to market for new treatments, therapies and devices. For more information, visit

About Oracle Industry Connect
Oracle Industry Connect, taking place in Boston March 25-26, 2014, brings industry leaders together to share deep domain expertise, insights and industry-specific best practices. This leadership event features customer-led content including visionary keynotes, executive-level networking and in-depth case studies designed to help organizations meet industry-specific challenges. For more information, please visit

Oracle and Java are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.

Safe Harbor Disclaimer
The above is intended to outline our general product direction. It is intended for information purposes only, and may not be incorporated into any contract. It is not a commitment to deliver any material, code, or functionality, and should not be relied upon in making purchasing decisions. The development, release, and timing of any features or functionality described for Oracle's products remains at the sole discretion of Oracle Corporation.

Contact Information